DEA has decided to simplify the process of research of hemp
Drug Enforcement Administration (DEA, US) in late December informed the US and the international community that existed until recently, requirements for the work in the study of the properties of cannabidiol (CBD) agreed to abolish and replace the old system of approval for the use of cannabis in clinical trials officially approved in accordance with the standards of Sanitary and Epidemiological Service, less cumbersome and more open scheme.
"This is certainly a very big step towards the recognition of the CBD, as officially approved and widely available drug. These changes to the existing approval process conducted by isledovany with hemp allow scientists to officially confirm the properties of the CBD for the treatment of various diseases by systematic and controlled trial of its action in humans, not animals, "says Seth Yakatan, is the CEO of one of the hemp companies. It was his firm is one of the leaders of the pharmaceutical market in the United States in the field of studying and developing drugs based on synthetic cannabidiol - hemp compound used as an alternative therapy in the treatment of osteoporosis, Prader-Willi syndrome and chronic obesity.
Because psychoactive hemp and its individual active ingredients on the list is strictly forbidden drugs, DEA is very carefully check the scientists interested in the possibility of conducting clinical trials in which cannabis use. Despite the desire of many people and organizations, both private and public, to identify precisely the impact of the various components of cannabis on human health and their usefulness in the treatment of various ailments, DEA, until recently, actively puts in the way of science bureaucratic obstacles. Acquaintance with study researches conducted by employees of the Office in the world, able to navigate that impeding the study of cannabis was "not productive and costly for the public service and the occupation of the whole society", which was followed by the immediate withdrawal of the old procedures for obtaining permits and materials for research. As the text of the letter sent by the organization, which had previously been denied trials or in obtaining new plant material, approved by the Sanitary Service epidimielogicheskoy, "changes in the regulatory processes DEA valid from 2016".
Previously, in addition to the main, it is a long and tedious process of evaluating "the expediency of work" by the DEA, scientists often had to submit to the Office of the repeated demands to provide them with additional materials for the research of the hemp plant, which contain a high rate of CBD, are grown on a single and state plantations of cannabis. This process took an unusually long time, stopping the scientists sometimes for years, until a petition, with great difficulty, held numerous bureaucratic authority of the Office, as well as sanitary and epidimielogicheskoy Service. Now researchers will be sufficient to obtain approval to conduct the work only once. Any modifications to the plan of work, scientists will be able to make in the course of research, without the need for re-approval from its regulator, begging for their permission to receive additional plant samples.
US DEA monitors Medical research together with colleagues from the Sanitary Service epidiemilogicheskoy that, in fact, have the primary jurisdiction over the components of the cannabis plant, as components of the plant are useful in medicine, medicinal compounds, subject to US standards of sanitary control. However, this rather strict Service has to be responsible for the regulation of processes konoplevodstva together with the DEA, because cannabis is a psychoactive controlled worldwide plant.